HM Payson & Co’s Celldex Therapeutics CLDX Stock Holding History

HM Payson & Co’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-960	Closed	-$32.6K	–	1005
2023 Q2	$32.6K	Buy	+960	New	+$32.4K	﹤0.01%	654

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

HM Payson & Co's CLDX Position: Q3 2023 in Review

HM Payson & Co sold out of Celldex Therapeutics (CLDX) in Q3 2023, closing a stake of 960 shares — an estimated $32.6K sold.

HM Payson & Co first reported a position in CLDX in Q2 2023 and held it in 1 quarter. The position peaked at $32.6K in Q2 2023. 144 funds tracked by Wall St. Rank hold CLDX as of Q3 2023.

HM Payson & Co reported no remaining Celldex Therapeutics position as of Q3 2023 after selling out during the quarter.
HM Payson & Co sold 960 Celldex Therapeutics shares in Q3 2023, an estimated $32.6K.
HM Payson & Co first reported a position in Celldex Therapeutics in Q2 2023 and held it in 1 quarter.
HM Payson & Co's Celldex Therapeutics position peaked at $32.6K in Q2 2023.
144 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2023.

Based on HM Payson & Co's 13F filing for Q3 2023, filed 6 Nov 2023.